Industry News

FDA approves first cancer biosimilar

20/09/2017

The US Food and Drug Administration has approved Amgen’s Mvasi (bevacizumab-awwb) as a biosimilar to Roche/Genentech’s Avastin (bevacizumab) for the treatment of multiple types of cancer, making it the first biosimilar approved in the country for the treatment of cancer.

More...

Abbott's flash glucose monitor to be made available on NHS

18/09/2017

Abbott's FreeStyle Libre – a flash glucose monitor that allows diabetes patients to track their blood sugar without pricking – will be reimbursed by the NHS from 1 November, subject to local health economy approval.

More...

U.S. 510(K) Clearance for Adherium’s Smartinhaler for AstraZeneca’s Symbicort Aerosol

08/09/2017

The U.S. FDA has cleared Adherium’s new SmartTouch for Symbicort® inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler.

More...

Bicycle Therapeutics could net over $400m in haemophilia deal

08/09/2017

Bicycle Therapeutics has teamed up with another biotech firm in a bid to tackle haemophilia and sickle cell disease in a deal which could net it over $400m.

More...

As Britain tops global university rankings, we must get Brexit right to stay there

06/09/2017

The Times Higher Education World University Rankings have, for the first time, named Oxford and Cambridge as the world’s two top universities. ABPI’s new Head of Education and Academic Liaison, Andrew Croydon, says this latest news adds to the weight of evidence that any Brexit deal should secure the UK’s access to the best science talent and research projects around the world.

More...

Swedish researchers build new tool to test coronary artery disease risk

05/09/2017

Researchers from Uppsala University in Sweden have built a new tool to identify patients who are at high-risk of coronary artery disease and could benefit from new, intensive preventive treatments.

More...

Tox prompts Janssen to drop MacroGenics' cancer antibody

04/09/2017

Janssen is ending a license deal with MacroGenics for duvortuxizumab, a CD19- and CD3-targeting drug for B-cell malignancies it paid $125 million upfront for in 2014, but isn’t severing ties with the biotech entirely.

More...

Report lays out new strategy for UK life sciences

04/09/2017

Industry-led plans to breathe new life into the UK’s £64-billion life sciences sector have been unveiled alongside details of £160 million in government funding to fuel progress in the field.

More...

Boosting immunotherapy by targeting cells’ recycling centers

30/08/2017

A subpopulation of cells in the immune system called CD8+ T cells are vital for the proper functioning of both vaccines and cancer immunotherapy treatments. When these cells divide, they become one of two types of pathogen-destroying soldiers: those that kill right away or those that remember the offender and provide long-term protection. Finding a way to boost the second variety of immune cells, called “memory” CD8+ T cells, could improve both vaccines and immunotherapies.

More...

Convenient Blood Test Detects Circulating DNA to Identify Recurrence of Tumors

30/08/2017

QIAGEN and colorectal cancer diagnostics company Clinical Genomics, tell us they have implemented the PAXgene® Blood ccfDNA Tube* sample collection in Clinical Genomics’ Colvera™ colorectal cancer (“CRC”) recurrence assay.

More...

Novartis breast cancer drug Kisqali wins EU approval

30/08/2017

Novartis has announced the launch of its new breast cancer drug Kisqali in the UK today following a green light from European regulators.

More...

100,000th Smartinhaler™ for Adherium

23/08/2017

Adherium Limited has recently manufactured and sold it’s 100,000th Smartinhaler™.

More...

James Mullen backs Vicarius’ $22M series A to equip ex-Biogen, Elan team to offer U.S. biotechs a route to Europe

23/08/2017

James Mullen has teamed up with colleagues from his days leading Biogen to help U.S. biotechs bring drugs to market in Europe. The resulting startup has raised CHF 21 million ($22 million) to get off the ground—and plans to return for about 10 times that once its business gets up to speed.

More...

Pfizer berates NICE over ALL drug decision

23/08/2017

Pfizer has said it is "very disappointed" by NICE’s decision to not recommend inotuzumab ozogamicin as a treatment for acute lymphoblastic leukaemia (ALL) – and that it believes NICE “inappropriately assessed the value of the medicine in making their determination of cost-effectiveness, using assumptions that are inconsistent with previous appraisals of other medicines in this disease area”.

More...

Celgene drops Sutro buyout option and refocuses deal on 4 I-O programs, freeing partner to pursue new alliances, IPO

11/08/2017

Celgene and Sutro Biopharma have revised the terms of the immuno-oncology pact they entered into in 2014. The reshuffle sees Celgene secure a stake in four assets that are advancing toward the clinic and opportunities to invest in Sutro at the expense of its option to buy the biotech outright.

More...

£2m UK consortium to tackle gene therapy

11/08/2017

A new consortium, led by Oxford BioMedica, will embark on a two-year, £2 million project focused on gene and cell therapy manufacturing.

More...

FDA clears AUM’s diagnostic cardiovascular device

11/08/2017

The US Food and Drug Administration (FDA) has cleared AUM Cardiovascular’s acoustic and electrocardiogram (ECG) device called CADence to aid detection of physiological and pathological heart murmurs.

More...

Silverstein-backed startup will test gene therapy for Parkinson's

10/08/2017

Regenxbio has joined forces with investment firm OrbiMed and a new nonprofit foundation to create Prevail Therapeutics, a startup focused on new biologics and gene therapies for Parkinson's disease (PD).

More...

LimFlow Pilot Study Yields Hope for “Desert Foot”

10/08/2017

A newly published pilot study into the LimFlow pDVA system suggests it offers an alternative option for the “desert foot.”

More...

Diabetes prescriptions rocket 80 percent in a decade

08/08/2017

Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.

More...

J&J Unveils New Neurovascular Business Name

02/08/2017

Sitting under the DePuy umbrella, Johnson & Johnson Medical Devices Companies has launched a new neurovascular business, to be called CERENOVUS.

More...

New hepatitis C therapies approved in Europe

02/08/2017

Patients with hepatitis C in Europe could soon gain access to two new pan-genotypic treatment options after the European Commission issued approval for AbbVie’s Maviret and Gilead’s Vosevi following an accelerated review.

More...

3 Things In Biotech You Should Learn Today:

02/08/2017

Summary AstraZeneca and Merck join forces in PARP inhibition.

More...

Gilead’s new HIV therapy under EU review

20/07/2017

European regulators are now reviewing Gilead’s fixed-dose combination of bictegravir (BIC), emtricitabine and tenofovir alafenamide as a treatment for HIV-1 infection.

More...

Breath sample cancer detection trials in Cambridge to widen

17/07/2017

Cambridge scientists will widen a cancer clinical trial to see if breath samples can be used to detect cancer in its early stages.

More...

GSK picks third target in Immunocore discovery deal

15/07/2017

GlaxoSmithKline has selected a third target in its collaboration with Oxford, UK-based Immunocore to discover multiple novel targets in cancer not addressable with antibody-based technologies.

More...

Novartis bags first-line approval for Zykadia

13/07/2017

The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.

More...

LifeArc teams up with UK defence lab and Canada’s CDRD

11/07/2017

LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets.

More...

GSK signs drug discovery pact with AI group Exscientia

09/07/2017

GlaxoSmithKline has signed a drug discovery pact with Dundee, UK-based artificial intelligence (AI) group Exscientia focused on multiple therapeutic areas.

More...

EU nod for Pfizer’s Besponsa

07/07/2017

Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL).

More...

MPs keen for close collaboration with EMA post Brexit

05/07/2017

British MPs say they are keen to secure a close working relationship with the European Union on drug regulation post Brexit to protect patient health and investment in the UK’s life sciences sector.

More...

Sandoz launches MabThera, Enbrel biosimilars in the UK

03/07/2017

Novartis group Sandoz has launched two new biosimilars across the UK potentially expanding access to biologic treatments for a range of inflammatory conditions and blood cancers.

More...

Ethicon’s New Power Stapler Delivers Control and Precision for Complex Surgeries

29/06/2017

J&J’s Ethicon has announced the launch of its ECHELON FLEX™ GST System (45mm) across Europe.

More...

Pfizer starts work on $236M biotherapeutics facility in Missouri

29/06/2017

Pfizer's biologic, vaccine and gene therapy researchers should have a new headquarters in mid-2019, now that construction work has started at a site in Chesterfield, Missouri.

More...

Joint expanded portfolio to provide integrated and seamless products and application services

29/06/2017

At the 17th Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery (WSSFN, June 26-29), Elekta (EKTA-B.ST) and Brainlab announced an agreement according to which Brainlab will be the authorized distributor of Elekta's stereotactic solutions for neurosurgery in selected markets.

More...

Novartis’ eye drug on par with Eylea but with fewer injections

21/06/2017

Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.

More...

3D-printed patch grows healthy blood vessels in mice, could treat ischemia

21/06/2017

A Boston University-led team has created a cell-infused 3D-printed patch that could become a new treatment option for challenging cases of ischemia.

More...

Cell Medica buys clinical-phase WT1-TCR cell therapy

21/06/2017

Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor (TCR) cell therapy. Catapult Therapy TCR developed the therapy as a treatment for blood cancers, but Cell Medica thinks it can retool it to take out solid tumors.

More...

Novartis’ CAR-T shows durable response in lymphoma patients

08/06/2017

Novartis’ closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR-T cell therapy in a mid-stage trial.

More...

Eko Devices gets FDA nod for its DUO digital stethoscope and ECG combo

08/06/2017

The FDA has cleared Eko Devices’ portable cardiac device that combines a digital stethoscope with electrocardiogram (ECG), allowing cardiologists and patients to better monitor heart disease, the company said.

More...

Johnson & Johnson’s $30B buyout suffers setback as Actelion antibiotic fails in one phase 3, succeeds in another

08/06/2017

Actelion has posted mixed late-phase data on its antibiotic cadazolid. The drug, which Johnson & Johnson is set to acquire in its $30 billion (€27 billion) takeover of Actelion, failed to match an old antibiotic in one study despite holding its own in another identical trial.

More...

Isansys Lifecare opens European headquarters in Brandenburg-Berlin Cluster

08/06/2017

Oxford, UK, 7th June, 2017:  Isansys Lifecare, the leader in new generation wireless patient monitoring systems, today announces the establishment of Isansys Lifecare Europe GmbH.

More...

Devices Aim to Identify Those “At Risk” of OIRD

05/06/2017

Medtronic hopes its new study will establish a role for pulse oximetry and capnography in patients on opioid medication.

More...

EU approves Opdivo for bladder cancer

05/06/2017

Bristol-Myers Squibb’s Opdivo has picked up approval for its eighth indication in Europe, having won clearance for the treatment of a subset of patients with metastatic urothelial carcinoma (mUC).

More...

UK’s F-star signs new deal with Merck

05/06/2017

Cambridge, UK-based F-star has signed a new collaboration with Merck under which the drug giant has the option to develop and commercialise five of its bispecific immuno-oncology antibodies.

More...

Cambridge life sciences firm Bicycle Therapeutics raises £40m

01/06/2017

Cancer drug firm Bicycle Therapeutics has raised £40m to help develop drug candidates to treat cancer.

More...

Horizon Discovery Group on 'path to profit'

01/06/2017

Horizon's CEO says he’s happy with the company’s “robust” revenue growth in 2016.

More...

UK set to become third global hub for biosciences as investment booms

31/05/2017

The UK is the world’s third largest global hub for innovation and development in the biosciences sector, new research has found.

More...

Iterum bags $65M for phase 3 trial of ex-Pfizer antibiotic

19/05/2017

Iterum has completed a $65 million (€58 million) Series B to equip it to take its antibiotic sulopenem through phase 3. The financing moves the total raised by the Irish biopharma company since it emerged last year armed with an antibiotic developed by Pfizer past the $100 million mark.

More...

FDA panel backs TransMedics’ lung transportation device

19/05/2017

The FDA’s Gastroenterology-Urology Devices Panel voted favorably on TransMedics’ perfusion system for the transportation of lungs for transplant.

More...

ARM wants to put a microchip in your brain

19/05/2017

Microchips get everywhere these days, and now ARM has partnered with an American university to try and find ways of putting one into your brain.

More...

Solar powered torch invented by Cambridge University students

19/05/2017

It may not sound like the most useful of devices, but a solar-powered 'torch' was one of the prize winners at Cambridge University Entrepreneurs' business plan competition.

More...

Pfizer doubles down on gene therapy pipeline with $70M Sangamo buy-in

15/05/2017

After deals and acquisitions with Spark Therapeutics and Bamboo, Pfizer is once again looking to bolster its rare and gene therapy pipeline as it outlines a new drug pact with Sangamo.

More...

Boston Scientific gets FDA nod for long-life cardiac implant

15/05/2017

Boston Scientific has received FDA approval for its Resonate line of high-voltage cardiac devices. The regulatory nod clears Boston Scientific to start selling devices it thinks can overcome reticence among physicians to use multipoint pacing products by diminishing concerns about battery life.

More...

X-Ray Capsule Endoscope Passes Manufacturing Tests

15/05/2017

Colorectal capsule innovator, Check-Cap Ltd., together with collaborator GE Healthcare, tell us they’ve achieved an important initial milestone in the development of high volume, X-ray capsule manufacturing capabilities.

More...

Samsung Launches New Ultrasound Systems

15/05/2017

Samsung is unveiling its new HS50 and HS60 ultrasound systems at the American College of Obstetricians and Gynecologists annual meeting in San Diego from May 6-9, 2017.

More...

Guardant gets $360M to sequence 1M cancer patients

15/05/2017

Guardant Health has raised $360 million to sequence the tumor DNA of 1 million cancer patients in the next five years. The SoftBank-led megaround positions the cancer blood test pioneer to push ahead with the sequencing initiative while expanding globally and stepping up its early detection R&D program.

More...

Why AstraZeneca's share price rocketed last week

15/05/2017

AstraZeneca's share price went up five per cent Friday morning (12th May) with news of positive results in a Phase III cancer drug trial.

More...

Cambridge University scientists giving hope to lung disease patients

15/05/2017

Cambridge University spin-out Z Factor hopes its treatment for lung disease will have the, er, X factor after raising £7m to help get new drugs to needy patients.

More...

A £35m new home for Cambridge life sciences firms

26/04/2017

New buildings to house up-and-coming Cambridge life sciences firms are to be constructed thanks to a £35m alliance between two of the city's research parks.

More...

Back to the Future star's foundation funds Cambridge firm's Parkinson's research

26/04/2017

Movie star Michael J Fox is backing the work of a Cambridge life sciences firm looking into a new treatment for Parkinson’s disease.

More...

Medivir posts lymphoma data, guns to get into phase 3

07/04/2017

Medivir has posted data from a phase 2 trial of its histone deacetylase (HDAC) inhibitor in patients with cutaneous T-cell lymphoma (CTCL). One regimen of the treatment triggered responses in 40% of subjects, a finding that has encouraged the Swedish pharmaceutical company to push ahead with plans to start a phase 3 trial later this year.

More...

Novocure's device-chemo combo boosts survival in pancreatic cancer

07/04/2017

Novocure, which markets a wearable device that treats brain cancer, unveiled positive survival data for the phase 2 pilot trial of its noninvasive therapy in patients with pancreatic cancer. The treatment was given alongside two chemotherapy drugs.

More...

Biotech high-fliers Abzena want to raise £25m

07/04/2017

Abzena is hoping to raise another £25m as it continues its bid for world domination.

More...

Australia’s Bionic Vision picks up $18M for ‘bionic eye’

07/04/2017

Bionic Vision Technologies raised AU$23.5 million ($18 million), which will go toward the development and commercialization of its device to restore vision to the blind.

More...

Could these companies unlock biology's potential?

07/04/2017

A new partnership could help unlock the potential of biology and address many of the challenges facing the modern world.

More...

AstraZeneca could slash £2bn R&D budget over NHS spending cap

27/03/2017

AstraZeneca says cost-saving plans for NHS could cause it to cut its £2bn-a-year R&D spend in the UK.

More...

Major pancreatic cancer study launched

27/03/2017

A new pancreatic cancer project has been launched to find ways to speed up scientific discovery to improve the survival rates of patients.

More...

More Texas Success for UK MedTech Companies

21/03/2017

A pioneering iPad case that enables clinical staff and surgeons to use iPads in sterile environments will soon be available in Texas. FlipPad® protects medical practitioners and patients from the risk of healthcare associated infections (HCAI) such as Norovirus and C-Difficile.

More...

Another Cambridge cluster biotech firm is snapped up by Americans

20/03/2017

A Newmarket life sciences supplier has been purchased by an American firm.

More...

'Huge advance' in fighting world's biggest killer

17/03/2017

An innovative new drug can prevent heart attacks and strokes by cutting bad cholesterol to unprecedented levels, say doctors.

More...

Cambridge firm Astex's joy at breast cancer treatment approval

17/03/2017

Astex Pharmaceuticals is celebrating after a breast cancer treatment it worked on was granted approval in the US.

More...

£3.5m to help Abzena cut heart attack and stroke risk

07/03/2017

Abzena and a leading university have received a £3.5m grant to develop a novel therapy for a disease which leaves patients at risk of a stroke or heart attack.

More...

£8m for Cambridge firm that can diagnose diseases in days

07/03/2017

Congenica has raised £8 million in a new funding round that will drive international expansion of its genome analysis business.

More...

Corin Launches FX Solutions Humelock Reverse Shoulder in U.S.

02/03/2017

European orthopaedic device comapny, Corin Group is to launch the Humelock Reversed Shoulder System in the U.S., Germany and U.K. Humelock is used to treat patients with both a massive rotator cuff tear and a severe form of shoulder arthritis.

More...

FDA clears St. Jude's latest FFR-measuring guidewire for coronary artery disease

24/02/2017

St. Jude Medical launched its newly FDA-cleared guidewire that measures fractional flow reserve. It is designed to improve percutaneous coronary intervention procedures in patients with narrowed coronary arteries.

More...

With FDA nod, Biotronik debuts first coronary stent in U.S.

24/02/2017

Biotronik has received FDA approval for a bare-metal stent designed to treat coronary artery disease. It is the company’s first coronary stent to hit the U.S. market.

More...

Cancer startup PMV Pharma gains impressive $74M B round

24/02/2017

New Jersey oncology biotech PMV Pharma has seen a healthy $74 million in funding from its Series B with help from InterWest Partners, Osage University Partners, Topspin Biotech Fund (which led this round), and its Series A lead investor OrbiMed.

More...

FDA clears 7SBio's 'virtually painless' blood collection device

24/02/2017

Seventh Sense Biosystems (7SBio) picked up an FDA nod for its “push-button” blood collection device, specifically to test the HbA1c levels in patients with diabetes and prediabetes. The company plans to add more assays for use with the device.

More...

Stemcell specialists are latest addition to Cambridge life sciences cluster

21/02/2017

The latest addition to the Cambridge life sciences cluster is a firm that provides reagents and tools to support researchers.

More...

Medtronic’s Signia™ Stapling System Adapts to Tissue Variability

21/02/2017

Medtronic plc has announced the launch of its Signia™ Stapling System which rather cleverly adapts to variability in tissue thickness.

More...

Mitotech eyes novel approach to treating Dry Eye Disease

14/02/2017

An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global increase in Dry Eye Disease. Currently, there are about 16 million people in the U.S. alone suffering from the condition, which is quickly becoming a common malady.

More...

Medtronic adds transradial diagnostic catheters to coronary product line

14/02/2017

Medtronic unveiled three new additions to its coronary portfolio Monday—a transradial diagnostic catheter and accompanying transradial devices to facilitate the treatment of coronary artery disease via the radial artery in the wrist.

More...

FDA Approval for First Balloon Expandable Stent Graft for Use in the Iliac Artery

06/02/2017

W. L. Gore & Associates tells us its GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) has received U.S. FDA approval for treatment of de novo or restenotic lesions found in iliac arteries, including lesions at the aortic bifurcation.

More...

J&J invests in Caelus, pens pacts to grow microbiome R&D

06/02/2017

Johnson & Johnson has unveiled a clutch of deals intended to grow its presence in the microbiome sector. The agreements will give J&J a stake in microbiota drug development shop Caelus Health—and links to DayTwo and the Weizmann Institute of Science to bolster its own activities.

More...

Abbott’s tiny wireless pacemaker is now MRI-compatible

06/02/2017

The FDA approved MRI-conditional labeling for Abbott’s tiny wireless pacemaker, making it the smallest and longest-lasting MRI-compatible device of its kind. The new labeling also applies to a pacing lead.

More...

Government must "learn from Cambridge" as it forms industrial strategy

30/01/2017

The Government must look to Cambridge as an example for the rest of the country when it prepares its new industrial strategy.

More...

Shark-inspired drug may help treat fibrosis, researchers say

30/01/2017

Australian scientists hope a drug that mimics part of a shark's immune system may help treat an incurable lung disease.

More...

Philips developing augmented-reality navigation for minimally invasive surgeries

18/01/2017

Philips revealed Thursday that it is developing a new surgical system that uses augmented reality to guide surgeons performing open and minimally invasive spinal surgery. The system combines external and internal images of the patient in real time to guide these procedures.

More...

AstraZeneca delays PD-L1 data in rejig of phase 3 program

18/01/2017

AstraZeneca has pushed back the estimated completion date for the phase 3 trial of its PD-L1 drug, a first-line treatment for non-small cell lung cancer (NSCLC). Progression-free survival data are now due to drop in the middle of this year, with an overall survival readout set to follow by 2018 at the latest.

More...

J&J teams with Orthocell on regenerative stem cell program

18/01/2017

Johnson & Johnson’s DePuy Synthes Products is collaborating with Orthocell on development of a stem cell-based approach to the regeneration of tendons. The partners are due to start a clinical trial of the candidate Ortho-ATI this quarter.

More...

SuliquaTM Approved in the European Union for the Treatment of Adults with Type 2 Diabetes

18/01/2017

Sanofi announced today that the European Commission has granted marketing authorization in Europe for SuliquaTM, the once-daily titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. Suliqua is authorized for use in combination with metformin to improve glycemic control when this has not been provided by metformin alone or metformin combined with another oral glucose lowering medicinal product or with basal insulin.

More...

Novartis, Pfizer join with Big Biopharma peers to create tech standards that streamline how HCPs access information

16/01/2017

Novartis, Pfizer and four more major biopharma companies have teamed with cloud computing player Veeva Systems to make it easier for healthcare professionals to access information about drugs. The partners are creating a single login for HCPs to use to access all online content, instead of having to enter a different username for each company.

More...

OxSonics bags $11M to take ultrasound tech into the clinic

16/01/2017

OxSonics and its sister company have raised $11 million to take ultrasound-based technologies into clinical development. The Series B will support development of technology that rapidly expands and collapses bubbles to improve drug delivery to solid tumors or treat chronic low back pain.

More...

U.S. Launch and First Commercial Use of Abbott’s New EnSite™ Precision Cardiac Mapping System

13/01/2017

Abbott has announced the U.S. launch and the first commercial uses of the new EnSite Precision™ cardiac mapping system and Advisor™ FL Circular Mapping Catheter, Sensor Enabled™ to map cardiac arrhythmias during ablation treatments.

More...

Why Sareum is in the money again

13/01/2017

Sareum is sharing in a $2m mile-stone payment stemming from its Chk1 inhibitor cancer drug candidate.

More...

Abcam making big progress in China

11/01/2017

Life sciences giant Abcam expects to report strong growth in the Chinese market when it delivers its interim results.

More...

Microsoft's Bill Gates awards $9m grant to Cambridge firm seeking HIV cure

10/01/2017

Bill Gates is pumping $9m into a Cambridge life sciences firm to strengthen its work developing novel treatments and vaccines for infectious diseases including HIV.

More...

Owlstone Medical Announces $11.55M USD (£9.3M GBP) Fundraising

09/01/2017

Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that it has successfully raised $11.55 million USD (£9.3 million GBP) financing. The investment round was led by existing investors, and will be used to commercially launch the company’s breath biomarker R&D services, including the opening of a new high volume clinical facility, and to fund ongoing clinical trials in lung and colon cancer screening. The funding follows the original investment of $7 million (£4.9 million) that spun Owlstone Medical out in June 2016.

More...

New year, new deals: J&J partners on 3D-printed meniscus, sleep coaching

09/01/2017

Johnson & Johnson Innovation unveiled 15 new collaborations, boosting its total deal count past 300. Most of the tie-ups surround drug discovery and development, but a few fall on the medical device side—including 3D printing an artificial meniscus and creating a personalized sleep coaching system for babies.

More...

How a licensing deal could net Babraham's Abzena $35m

03/01/2017

Abzena has received an early Christmas present with the news that it could be in line for $35m after signing a licensing agreement.

More...

Cambridge research could lead to new treatments for vascular disease

22/12/2016

Cambridge University is teaming up with King’s College London and a pharmaceutical firm to repurpose drugs in the hope that they can treat vascular disease.

More...

Megamerger era may be over, but M&A spend still hovers around bigger deals

22/12/2016

Following 2014’s summer of “med tech merger mania,” 2015 was a record-breaking year for med tech M&A--even if we exclude the $50 billion Medtronic-Covidien tie-up, 2015 still beats every other year in the past decade. But what of 2016?

More...

Multiple sclerosis drug 'a landmark'

22/12/2016

A drug that alters the immune system has been described as "big news" and a "landmark" in treating multiple sclerosis, doctors and charities say.

More...

MicroPort invests in Lombard, lands rights to stent grafts

22/12/2016

MicroPort Scientific has invested $15 million in Lombard Medical as part of a deal that gives it rights to stent grafts in China and Brazil. The pact gives Lombard a partner capable of commercializing its Aorfix and Altura stent grafts in key global markets, plus an infusion of capital and component supply pact.

More...

This AstraZeneca drug could replace chemotherapy as standard lung cancer treatment

22/12/2016

An AstraZeneca drug could replace chemotherapy as the new standard treatment for lung cancer after it performed well in a trial.

More...

Ten people to get NHS bionic eyes

22/12/2016

The NHS will pay for 10 blind patients to have "bionic eyes" to help treat an inherited form of blindness. The bionic eye is a retinal implant which interprets images captured by a miniature video camera worn on a pair of glasses.

More...

FDA clears St. Jude's latest cardiac mapping device

21/12/2016

St. Jude Medical picked up an FDA nod for its new cardiac mapping system and a sensor-enabled catheter, which guides clinicians treating patients with arrhythmias so they can perform procedures more quickly and more accurately.

More...

New ABHI Texas Mission Spells Opportunity for UK MedTech

21/12/2016

Following a successful “Mission” in October , UK industry body the Association of British Healthcare Industries(ABHI), now plans a re-run in early March 2017. The ABHI is inviting applications from interested MedTech companies.

More...

Providence Medical raises $11M to expand spinal fusion portfolio

21/12/2016

Providence Medical Technology reeled in $10.5 million to build up and commercialize its portfolio of cervical-fusion devices used in spinal surgery.

More...

Codman Neuro Expands Neurovascular Portfolio with Acquisition of Pulsar Vascular

19/12/2016

Codman Neuro has announced its acquisition of Pulsar Vascular Inc. with its breakthrough platform technology for the neurovascular treatment of complex aneurysms.

More...

FDA clears integration of J&J, Welldoc tech for real-time diabetes management

19/12/2016

In March, Johnson & Johnson tapped mobile health tech player Welldoc to incorporate its diabetes management platform into J&J’s latest blood glucose monitor. Now, the pair is announcing FDA clearance of the wireless integration between the two systems.

More...

Novocure's noninvasive brain cancer therapy could succeed in ovarian cancer

19/12/2016

Phase 2 pilot data show that Novocure’s noninvasive cancer treatment, initially approved for glioblastoma, is safe and effective when delivered alongside paclitaxel to patients with recurrent ovarian cancer.

More...

Lumendi's colonoscope stabilizer picks up FDA nod

19/12/2016

Lumendi is developing devices to shift invasive gastrointestinal surgeries toward minimally invasive endoluminal procedures—that is, procedures done entirely from within the intestine. The devicemaker earned FDA clearance for its endoscope stabilizer that facilitates endoluminal treatments.

More...

Akili, Pfizer successfully gamify Alzheimer's

13/12/2016

Back in 2014, Pfizer teamed up with Akili Interactive Labs to see if a video game could really detect early signs of Alzheimer’s. Now, the pair is presenting data showing that Akili’s tech can differentiate between patients with and without brain amyloidosis, and could lay the foundation for a noninvasive way to detect amyloid deposits in the brain.

More...

Medtronic integrates CGM, Fitbit data into mobile app

13/12/2016

Medtronic and Fitbit are joining forces to integrate diabetes patients’ activity tracking and blood glucose data in a single app, with eyes on improving diabetes management by helping patients better understand the effects of exercise on blood glucose.

More...

Elucigene partners with Congenica on New NGS Cystic Fibrosis Kit

07/12/2016

The emergence of new therapies that treat the causes of cystic fibrosis is creating an imperative for more accurate variant analysis. To address this demand Elucigene Diagnostics, a leading developer and distributor of prenatal and human genetics diagnostics, in partnership with Congenica, a leader in genomic analysis and interpretation, has developed a new cystic fibrosis (CFTR) gene analysis kit. The “all-in-one” CFTR gene analysis kit allows sample processing, analysis with next generation sequencing (NGS), and variant interpretation, streamlining the diagnostic process.Dr Mark Street-Docherty, Commercial Manager for Elucigene Diagnostics says: “Congenica has produced a bespoke analysis and reporting pipeline to support customers using our new targeted NGS kit for cystic fibrosis (CFTR) gene analysis.“The Congenica and Elucigene partnership will provide support to CFTR diagnostics, reporting only clinically relevant information, and therefore simplifying analysis associated with competitor whole genome approaches.“Congenica’s Sapientia™ platform will form part of our offering to the customer, enabling seamless sample processing and analysis.”Craig Taylor, Head of Business Development for Congenica, says: “We’re very excited about partnering with Elucigene and introducing Sapientia to clinical labs around the world, enabling them to benefit from the same interpretation and analysis platform employed by leading NHS Hospitals in the UK. This partnership illustrates the flexibility of Sapientia, which can be customized according to partner needs."Cystic fibrosis is an inherited disorder affecting 70,000 people worldwide. The new product is the first in Elucigene’s range to embrace Next Generation Sequencing (NGS). Elucigene has developed probes specifically designed to deeply sequence, with higher confidence, the areas of the CFTR gene where the targeted variants occur. This has increased the detection rate from between 85 to 95 per cent to over 99 per cent for some populations.

More...

Owlstone Medical’s ReCIVA Named Invention of the Year in Top 50 Digital Health Awards

07/12/2016

Cambridge, UK, 6 December 2016: Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced today that its ReCIVA breath sampling and analysis technology has been named Invention of the Year in the 2017 Top 50 in Digital Health Awards. Each year ahead of the JP Morgan Health Conference in San Francisco, fifty of the leading entrepreneurs, investors, technologists, reporters, and providers dedicated to bringing technological advancements to healthcare are recognized at the Top 50 in Digital Health Dinner hosted by Rock Health, Fenwick & West, Goldman Sachs, and Square 1 Bank. Within the Top 50, a number of individuals and organizations are awarded through public nominations and votes from the digital health community for making exceptional progress in driving resources, attention, and innovation toward a massively better healthcare system. Owlstone Medical uses the Respiration Collector for In Vitro Analysis (ReCIVA), in combination with the Field Asymmetric Ion Mobility Spectrometer (FAIMS) sensor platform, to accurately and selectively detect targeted biomarkers of disease in breath (and other bodily fluids). Billy Boyle, co-founder and CEO at Owlstone Medical, said: “We are delighted that ReCIVA has been named Invention in the 2017 Top 50 Digital Health Awards. Our vision is to save 100,000 lives and $1.5B in health care costs by 2020 with a breath sampling and analysis technology that can diagnose cancer and other diseases earlier than existing tests. This allows for more effective treatment and ultimately, better patient survival rates and reduced treatment costs.” 

More...

Boston Scientific Earns Perfect Score on Human Rights Campaign's Corporate Equality Index

06/12/2016

Boston Scientific has been recognized for the third consecutive year as a “Best Place to Work” by the Human Rights Campaign Foundation. The company earned a score of 100 percent on the annual Corporate Equality Index (CEI), a national benchmarking survey and report on corporate policies and practices related to lesbian, gay, bisexual and transgender (LGBT) workplace equality. The rankings evaluate businesses on LGBT-related policies and practices, including equal opportunity workplace protections, domestic partner benefits, transgender-inclusive health care benefits, competency programs and public engagement with the LGBT community.

More...

CE Mark for World’s First Sterile, Single-Use Endoscope for Colonoscopies

06/12/2016

Robotic endoscope specialist, invendo medical GmbH, tells us it has received CE Mark for the invendoscope™ SC200, the world’s first sterile, single-use colonoscope.

More...

Platypus venom could give rise to a new class of diabetes treatments

05/12/2016

Australian scientists have found a potential new angle for diabetes treatment in the unlikeliest of places: the venom of the platypus and the echidna. These animals produce a stable version of the hormone glucagon-like peptide-1, which could lead to a longer-lasting version of the hormone for people with Type 2 diabetes.

More...

Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities

02/12/2016

 Boston Scientific Corporation today announced a definitive agreement to acquire certain manufacturing assets and capabilities of the Neovasc, Inc., advanced biological tissue business, as well as a 15% equity stake in Neovasc, for a total of $75 million in cash. The Neovasc advanced biological tissue business makes elements used in transcatheter heart valves, including the Boston Scientific Lotus™ Valve System.* Upon completion of the transaction, the Neovasc advanced biological tissue capabilities will be integrated into the Boston Scientific structural heart business for use in the manufacturing of the Lotus valve and future heart valve technologies. 

More...

Boston Scientific acquires single-use uterine polyp remover from Distal Access

30/11/2016

Boston Scientific is picking up a single-use device for the removal of uterine polyps in its acquisition of Distal Access’ gynecology and urology portfolio. The financial details of the deal were not disclosed.

More...

Edwards strikes $690M deal to buy Valtech Cardio

30/11/2016

Edwards Lifesciences has penned a deal to buy Valtech Cardio for up to $690 million, less than the heart valve company looked set to be acquired for last year. The new agreement will see Edwards pay $340 million in stock and cash upfront aEdwards Lifesciences has penned a deal to buy Valtech Cardio for up to $690 million, less than the heart valve company looked set to be acquired for last year. The new agreement will see Edwards pay $340 million in stock and cash upfront and up to $350 million in milestones to acquire Valtech and its system for transcatheter repair of the mitral and tricuspid valves.

More...

Hemosep: the machine set to revolutionise blood transfusions

28/11/2016

The idea of being able to recover a patient’s own blood and put it back into their body is not new, but until now it has been expensive and largely unworkable. Autotransfusion, as it is known, has typically used large, complex, centrifugal devices that require skilled operators, take a lot of time and are very expensive. The cumbersome machines used in many hospitals return just the red blood cells, eliminating the platelets needed for clotting and the white cells required to fight infection. That can lead to complications.

More...

Predatory bacteria can wipe out superbugs, says study

24/11/2016

Predatory bacteria - that eat others of their kind - could be a new weapon in the fight against superbugs, say UK researchers.

More...

Boston Scientific To Participate In Citi 2016 Global Healthcare Conference

23/11/2016

Boston Scientific Corporation is scheduled to participate in the Citi 2016 Global Healthcare Conference on December 7 in New York City.

More...

Dementia rates show signs of falling

23/11/2016

There is growing evidence that the dementia crisis may not be as bad as first feared, say researchers.

More...

PM signals £2bn a year science funding increase

23/11/2016

Prime Minister Theresa May has unveiled plans to invest an extra £2bn a year in science by 2020.

More...

Pulmonx Zephyr® EBV gets into COPD “Bible”

23/11/2016

For the first time, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has recommended use of endobronchial valves in bronchoscopic lung volume reduction for patients with advanced emphysema and absence of collateral ventilation.

More...

Direct Flow raises $27 million

25/07/2016

Direct Flow Medical raised raised $27.1 million in a new round of financing through the sales of select stock and warrants.

More...

New AngioDynamics CEO: I'll focus on current business now, M&A next phase

24/05/2016

Jim Clemmer said he's focused first on the existing business at the medical device manufacturing company in Latham he now leads.

More...

Why Boston Scientific Corporation Rose 15.7% in April

11/05/2016

A stellar earnings report pumped up shares of the cardiac device specialist.

More...

Ivoclar Vivadent announce global sales growth in 2015

07/04/2016

 

More...

Startup gains FDA nod for wearable EKG cardiac arrhythmia monitor

18/03/2016

The FDA has cleared the MoMe Kardia electrocardiogram device from startup InfoBionic to diagnose cardiac arrhythmias. It's a big step up from traditional cardiac monitors and includes three different monitoring types that typically require discrete devices.

More...

Olympus Unveils Big Screen Surgery In 4K

18/03/2016

Olympus has unveiled the VISERA 4K UHD System, its state-of-the art Big Screen surgical system, at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2016 Annual meeting in Boston.

More...

MRI Compatibility CE Mark for St. Jude Medical Nanostim Leadless Pacemaker

18/03/2016

With a new CE mark approval, St. Jude Medical, Inc. has now added magnetic resonance (MR) conditional labeling for 1.5 T scans for its Nanostim™ leadless pacemaker.

More...

CE Mark for K2M’s Next-Generation Cervical Disc System

01/02/2016

Complex spine specialist K2M Group Holdings, Inc., says it has received a CE Mark for the RHINE™ Cervical Disc System which it describes as its next-generation cervical artificial disc replacement featuring proprietary molding technology.

More...

Advanced Cardiac Therapeutics Completes Successful First-in-Man

01/02/2016

Advanced Cardiac Therapeutics, Inc., a developer and manufacturer of a proprietary and unique open-irrigated radio frequency (“RF”) ablation technology, tells us that its technology has been successfully used to treat 12 patients suffering from Atrial Fibrillation (“AFIB”) in Prague, Czech Republic.

More...

Study finds Masimo respiratory monitor more useful in tracking IV patients

22/01/2016

Longtime oxygen monitor leader Masimo ($MASI) is touting a study that found its acoustic respiration rate as measured by its Rainbow Acoustic Monitoring (RAM) is more effective at monitoring dental patients who are under intravenous anesthesia than conventional capnography.

More...

NuVasive Buys Ellipse Technologies for $380Million

20/01/2016

Spinal device company, NuVasive, Inc. is to buy “skeletal deformities” specialist Ellipse Technologies, Inc., for a $380 million upfront cash payment and a potential $30 million milestone payable in 2017 related to the achievement of specific revenue targets.

More...

FDA Approval for Perceval Sutureless Heart Valve

20/01/2016

LivaNova PLC has gained U.S. FDA approval of its Perceval Sutureless Heart Valve. Commercial distribution of the device in the U.S. will commence over the coming quarter.

More...